Glenmark obtains FDA nod for generic Evekeo

The Food and Drug Administration has given its blessing to Glenmark for amphetamine sulfate tablets in dosage strengths of 5 mg and 10 mg, a generic of Arbor Pharmaceuticals’ Evekeo tablets. 

The drug is indicated to treat attention deficit hyperactivity disorder in children ages 3-12, adolescents, and adults.

Evekeo tablets had a market value of approximately $21.5 million for the 12-month period ending November 2020, according to IQVIA.